For a start, it’s not just the cost.
Testosterone therapy, a treatment for low testosterone, costs about £40,000 a year, with an average of £30,000.
It is also not cheap.
The cost of the treatment can vary from about £400 a year for a woman to up to £8,000 for a man.
The National Institute for Health and Care Excellence (NICE) has warned that testosterone therapy could have “negative consequences for the health of men, women and children”.
And there is evidence that it can cause side effects.
For example, research published in 2014 found that some men had high levels of a protein that helps protect against prostate cancer.
Testotheres use testosterone to regulate the production of a hormone called androgens.
But men can also get testosterone from the body.
The NHS pays for the treatment, which is called testosterone enanthate, in a bid to help men’s testosterone levels reach healthy levels.
The treatment, called androgen therapy, also uses testosterone to help treat low testosterone.
For men with low testosterone levels, a testicle cancer drug, a hormone known as aromatase inhibitor, can lower testosterone levels.
However, the drug is still only available to men.
And for women, a new test called an aromatiser can reduce testosterone levels to the level of a normal man.
These drugs are expensive and have not yet been approved for use in men.
Testosterones have been used to treat low levels of testosterone in men since the 1930s, and the treatment has been around since the 1960s.
The new treatment is a new form of testosterone therapy, which has the same side effects as the old one, but the side effects are far less severe.
Dr Paul Hirsch, of the University of Pennsylvania, said testosterone therapy should be considered as an option for those who suffer from low testosterone but have not had surgery to remove their prostate.
“If a man has low testosterone and he has a benign prostate, it might be that he needs testosterone enantio [androgen therapy],” he said.
“Androgens can be very useful for people who have not been diagnosed as having low testosterone.”
Dr Hirsch said the new testosterone therapy was also “very expensive” because it costs about 20 times more than the old testosterone therapy.
Dr Hensch also warned that the treatment could increase the risk of prostate cancer in men with prostate cancer and prostate enlargement.
“This is a very expensive therapy,” he said, “but it’s very promising.
It may work in men who have low testosterone for a long time, but it’s probably not the best way to treat prostate cancer.”
Dr Paul says that the NHS should fund the treatment for men who are at high risk of developing prostate cancer or men who suffer low testosterone from prostate cancer but who do not have a condition that makes it difficult to produce testosterone.
He says the treatment should also be available to women with low levels.
“I do not think we should be doing this treatment unless we can prove that it is safe and it has a good side effect profile,” he says.
Dr Phil Wilson, a specialist in male androgen treatment at the University Hospital in Newcastle, UK, said the treatment was not a “silver bullet” because of the risks of side effects for some men, such as erectile dysfunction.
“There are some who will say that the benefits are not enough to justify the costs,” he told the BBC.
What are the risks? “
For those who have been diagnosed with low test levels, and who are trying to get testosterone back, this could be a good option.”
What are the risks?
There are also some concerns.
Men who are already using testosterone-lowering drugs will not benefit from the new treatment.
There are fears that testosterone enantiomer could cause side-effects.
Dr Wilson said that men with normal testosterone levels should not take the testosterone enanto, as it would increase their risk of side-effect.
He said it would be better for men to get an aromatic replacement therapy.
“Aromatic replacement therapies are effective in reducing androgen levels and improving health and sexual function,” he added.
But he added that it was important that the new therapy was used by men who had had surgery.
Dr Peter Janssens, a researcher at the National Institute of Health and Medicine (Niemann-Pickering), said the NHS had a “moral responsibility” to “proactively promote” testosterone therapy for men.
“The National Institute and NICE have recommended that the Government support this and the NHS has a responsibility to support it,” he wrote in a blog post.
“But the reality is that, until we have a better understanding of how the benefits of testosterone treatment can be delivered, there is no reason why we should not fund the cost of testosterone enananthate therapy for those men who need